financetom
Business
financetom
/
Business
/
Apple facing hurdles in adapting Baidu AI models for China, The Information reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Apple facing hurdles in adapting Baidu AI models for China, The Information reports
Dec 4, 2024 7:33 AM

Dec 4 (Reuters) - Apple ( AAPL ) and Baidu ( BIDU ) are

working to add AI features to iPhones sold in China, but are

facing hurdles that could hurt the tech giant's phone sales in

the country, The Information reported on Wednesday.

The companies, which are adapting Baidu's ( BIDU ) large language

models for iPhone users, are grappling with issues such as the

LLMs' understanding of prompts and accuracy in responding to

common scenarios, according to the report.

Apple ( AAPL ) and Baidu ( BIDU ) did not immediately respond to Reuters'

requests for comment.

Sales of iPhone in China slipped 0.3%, while rival Huawei

posted a 42% surge in sales in the third quarter, research firm

IDC had said in October, as competition intensifies in the

world's largest smartphone market.

Apple's ( AAPL ) long-awaited iPhone 16 launch in September had drawn

scorn in China for its lack of artificial intelligence features.

Also, Apple's ( AAPL ) privacy policies do not allow collection of

data from iPhone users who make AI-related queries, but Baidu ( BIDU )

wants to save and analyze this data, according to the report.

Baidu's ( BIDU ) most advanced model, Ernie 4.0, is being employed as

the foundation for Apple's ( AAPL ) genAI services on the iPhone, Mac and

iPad, The Information said, citing people familiar with the

matter.

Siri will also use Baidu's ( BIDU ) AI models, according to the

report.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TScan Therapeutics Q3 revenue jumps
TScan Therapeutics Q3 revenue jumps
Nov 12, 2025
Overview * TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements * Net loss for Q3 2025 increased due to higher R&D expenses * Company reached FDA agreement on pivotal trial design for TSC-101 Outlook * Company expects cash reserves to fund operations into the second half of 2027 * Enrollment in solid tumor trial paused to...
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
Nov 12, 2025
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory...
Ovid Therapeutics Q3 revenue slightly beats expectations
Ovid Therapeutics Q3 revenue slightly beats expectations
Nov 12, 2025
Overview * Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations * Meg Alexander appointed CEO, effective January 2026 Outlook * Ovid plans Phase 2a trial for OV329 in Q2 2026 * Company expects OV350 data in Q4 2025 * Ovid anticipates OV4071 clinical trial start in Q2 2026 Result Drivers * Research and development expenses were $5.9...
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Nov 12, 2025
07:14 AM EST, 11/12/2025 (MT Newswires) -- Loblaw Companies ( LBLCF ) said Wednesday that third-quarter adjusted earnings and revenue both rose, with both measures beating estimates. Adjusted earnings increased 8% to $828 million or $0.69 per diluted share, from $767 million, or $0.62 per diluted share in the prior year period. The result was a cent above the consensus...
Copyright 2023-2026 - www.financetom.com All Rights Reserved